Teriparatide

A recombinant PTH fragment approved for severe osteoporosis, and one of the few anabolic bone therapies available.

Teriparatide is classified as a parathyroid hormone analog. Its current development status is: fda-approved (branded forms). Multiple randomised controlled trials in humans support the primary claims made for this compound.

The Peptide Institute tracks Teriparatide because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.